Sherlock Biosciences Named PM360 Trailblazer 2022 Company of the Year for Medical Device/Diagnostics
Watertown, Mass., September 26, 2022 – PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Sherlock Biosciences as the Medical Device/Diagnostics Company of the Year.
Sherlock is dedicated to breaking down diagnostic barriers and bringing health information to people around the world. Powered by CRISPR and synthetic biology, Sherlock’s proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection. The company is developing products that can operate at ambient temperature without complex instrumentation, opening up a wide range of applications in low resource settings including the home.
“We are honored that Sherlock has been recognized by PM360 as the Medical Device/Diagnostics Company of the Year,” said Bryan Dechairo, President and CEO of Sherlock Biosciences. “This recognition is not only a testament to our incredible team, but also to the innovations we are driving in the field and the impact they will have in democratizing and decentralizing the at-home testing market.”
Since 2009, the PM360 Trailblazer Awards have recognized outstanding achievement and innovation in healthcare marketing. Each year, nominations are judged by the PM360 Editorial Advisory Board, a distinguished cross-section of industry experts. One winner was selected in each of the five Company of the Year categories: Pharma/Biotech Company, Medical Device/Diagnostics Company, Specialty Pharma/Biotech Company, Advertising Agency, and Supplier/Vendor. Winning companies are selected based on their ability to excel in three main aspects: innovation, talent development, and social responsibility.
“The innovation displayed by each of this year’s winning companies stood out for its impact on the industry and patient care, including the advancements made by Amgen in inflammation, oncology, general medicine, and biosimilars; Sherlock Biosciences’ first-ever FDA authorized CRISPR-based diagnostic device; Travere’s pipeline of potential first-in-class medicines targeting rare diseases; EVERSANA INTOUCH’s newly formed combined next-generation agency; and GoodRx’s cost-saving tools for prescriptions,” says Anna Stashower, CEO and Publisher of PM360. “But what truly makes these companies special is the work they are doing outside of the industry to better their communities and the environment, while also going above and beyond internally to provide employees with offerings that can help them grow and thrive.”
In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives. The winners were honored during a gala on September 22, 2022 held at Gotham Hall in New York City. The winners will be featured in the October issue of PM360 and on www.pm360online.com.
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.
By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.
About Sherlock Biosciences
Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Through our engineering biology tools, CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™, we are bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology. For more information, please visit www.sherlock.bio.